Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Trending Stock Alerts

ALIM Stock - Alimera Sciences Stock Trading


home / stock / alim

ALIM ALIM Quote ALIM Short ALIM News ALIM Articles ALIM Message Board

MWN AI Summary *

Alimera Sciences Inc. (NASDAQ: ALIM) is a biopharmaceutical company that focuses on the development and commercialization of biopharmaceuticals for diseases of the retina. Founded in 2003 and headquartered in Atlanta, Georgia, Alimera primarily concentrates on products that address diabetic macular edema (DME), a condition that affects the eyes and can lead to vision loss.

The company's most notable product is Iluvien, an implantable drug delivery device designed to provide sustained release of fluocinolone acetonide, a steroid that reduces inflammation and controls swelling in the retina. Iluvien is approved for use in patients with chronic DME and is positioned as a long-term treatment option, requiring administration only once every 36 months. The innovative design of the device allows for a targeted approach, potentially leading to better patient outcomes and fewer visits to healthcare providers.

Alimera focuses on expanding its market reach and enhancing its product offerings. The company has been actively involved in clinical trials to assess the efficacy of Iluvien in various other retinal conditions, indicating a commitment to understanding and addressing unmet medical needs within the ophthalmic space. In addition to Iluvien, Alimera is exploring other therapeutic candidates, boosting its pipeline and enhancing potential revenue streams.

Financially, Alimera has experienced ups and downs typical of biotechnology firms, with market volatility influenced by product approvals, earnings reports, and broader market conditions. The company's strategic partnerships and careful financial management have been crucial in navigating these challenges.

As of October 2023, Alimera Sciences continues to focus on growth through innovation and attracting investors interested in the specialized field of ophthalmology, positioning itself as a key player in the biopharmaceutical landscape.

MWN AI Analysis *

As of late 2023, Alimera Sciences Inc. (NASDAQ: ALIM) presents an intriguing investment opportunity within the biotechnology sector, specifically focusing on retinal diseases. The company’s lead product, ILUVIEN, is an injectable treatment for chronic diabetic macular edema (DME), a condition that affects the eyes and can lead to significant vision loss. Evaluating Alimera's financial performance, growth prospects, and market conditions is essential for potential investors.

Recent financial results indicate that Alimera has made strides in its revenue generation, particularly through increased product sales and strategic partnerships. The continued acceptance of ILUVIEN in international markets, combined with its expanding distribution network, signals robust demand for its treatment options. However, it’s crucial to monitor the ongoing expenses related to research and development, as well as regulatory requirements, which can impact profitability.

Moreover, the biotechnology sector is influenced by broader market conditions, including interest rates and investor sentiment toward small-cap stocks. With a market capitalization that classifies Alimera as a micro-cap stock, volatility can be expected. Investors should keep an eye on macroeconomic indicators and sector-specific trends that may affect the biotech industry’s performance.

The company’s focus on expanding its product pipeline could also be a significant driver of growth. Yet, the success of future products will hinge on the results of clinical trials and regulatory approvals, which carry inherent risks. Therefore, due diligence is crucial.

In conclusion, while Alimera Sciences holds potential for long-term growth, investors should approach with caution, balancing the anticipation of upside opportunities against the backdrop of inherent risks within the biotechnology field. A diversified investment strategy may be prudent, allowing exposure to Alimera while managing overall portfolio risk. Regularly monitoring the company’s developments and market conditions will also be essential in making informed investment decisions.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Alimera Sciences Inc. (NASDAQ:ALIM)

Alimera Sciences is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN(R) is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. A $2B global market, DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema leading to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology.

Quote | Alimera Sciences Inc. (NASDAQ:ALIM)

Last:$5.54
Change Percent: -0.18%
Open:$5.55
Close:$5.54
High:$5.56
Low:$5.53
Volume:2,679,904
Last Trade Date Time:09/13/2024 03:00:00 am

News | Alimera Sciences Inc. (NASDAQ:ALIM)

  • Expected US Company Earnings on Thursday, October 24th, 2024

    Be Semiconductor Industries NV New York Shares (BESIY) is expected to report for Q3 2024 Carrier Global Corporation (CARR) is expected to report $0.81 for Q3 2024 Ameris Bancorp (ABCB) is expected to report $1.26 for Q3 2024 CBRE Group Inc Class A (CBRE) is expected to report $1.06 fo...

    • October 24, 2024 07:00:20 am

    • |
    • US Earnings Reports
    • |
      • ALIM Stock
      • ALIM Quote
      • ALIM Short
      • ALIM News
      • ALIM Articles
      • ALIM Message Board
  • ANI Pharmaceuticals completes purchase of Alimera Sciences

    2024-09-16 09:04:44 ET More on Alimera Sciences Alimera Sciences: Deal Closing After All, CVR Still Attractive Alimera Sciences: Cheap CVR Optionality Alimera Sciences falls after it sues ANI Pharmaceuticals to close deal (update) Biggest stock movers today: ...

    • September 16, 2024 09:04:44 am

    • |
    • SeekingAlpha
    • |
      • ALIM Stock
      • ALIM Quote
      • ALIM Short
      • ALIM News
      • ALIM Articles
      • ALIM Message Board

Message Board Posts | Alimera Sciences Inc. (NASDAQ:ALIM)

Subject By Source When
agreed The Night Stalker investorshub 05/18/2023 2:32:25 PM
$ALIM I got in for a play MiamiGent investorshub 05/18/2023 1:45:59 PM
Alimera Acquires U.S. Commercial Rights to YUTIQ subslover investorshub 05/18/2023 12:24:59 PM
$ALIM best news of the day whytestocks investorshub 05/17/2023 10:09:44 PM
is it bear time? Or do we go bull? mick investorshub 05/17/2023 8:52:48 AM

MWN AI FAQ **

What recent developments or partnerships has Alimera Sciences Inc. (NASDAQ: ALIM) undertaken that might influence its market position in the ophthalmology sector?

Alimera Sciences Inc. (NASDAQ: ALIM) recently entered partnerships to advance its innovative retinal disease treatments and expand its distribution network, which may enhance its competitive standing in the ophthalmology market and drive increased adoption of its products.

How does Alimera Sciences Inc. (NASDAQ: ALIM) plan to address potential competitive threats in the treatment of retinal diseases?

Alimera Sciences Inc. plans to address potential competitive threats in the treatment of retinal diseases by focusing on innovation, developing advanced therapeutics, strengthening partnerships, and enhancing their market presence to differentiate their offerings.

Can you provide insights into the financial health and revenue trends of Alimera Sciences Inc. (NASDAQ: ALIM) over the past few quarters?

As of October 2023, Alimera Sciences Inc. (NASDAQ: ALIM) has demonstrated fluctuating revenue trends, with recent quarters showing modest growth driven by increased sales of its retinal disease treatments, but continues to face challenges in overall financial health due to ongoing operational costs.

What are the key growth catalysts that investors should be aware of regarding Alimera Sciences Inc. (NASDAQ: ALIM) in the coming years?

Key growth catalysts for Alimera Sciences Inc. include the expansion of its Iluvien product in treating chronic diabetic macular edema, potential new product developments, strategic partnerships, and advancements in its research pipeline to enhance treatment options.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get ALIM Alerts

News, Short Squeeze, Breakout and More Instantly...

Alimera Sciences Inc. Company Name:

ALIM Stock Symbol:

NASDAQ Market:

-0.18% G/L:

$5.54 Last:

2,679,904 Volume:

$5.55 Open:

$5.54 Close:

Alimera Sciences Inc. Website:

Alimera Sciences Inc. Logo

Ad

Trending Stock Alerts
RECENT ALIM NEWS
  • ALIM - Expected US Company Earnings on Thursday, October 24th, 2024

    Be Semiconductor Industries NV New York Shares (BESIY) is expected to report for Q3 2024 Carrier Global Corporation (CARR) is expected to report $0.81 for Q3 2024 Ameris Bancorp (ABCB) is expected to report $1.26 for Q3 2024 CBRE Group Inc Class A (CBRE) is expected to report $1.06 fo...

  • ALIM - ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

    Strengthens Rare Disease segment as largest driver of future growth , adding approximately $105 million in 2024 revenue on a pro forma basis Adds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI’s foothold in strategic...

  • ALIM - (ALIM) Long Term Investment Analysis

    2024-09-14 02:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get ALIM Alerts

Get ALIM Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1